Neutropenia after myeloablative conditioning regimens in cord blood transplant (CBT) recipients or following intensive chemotherapy for leukemia is associated with a high mortality risk from infectious complications necessitating interventions to reduce this neutropenic period. 1,2 Several ex vivo expansion approaches have been identified that are capable of generating short-term hematopoietic repopulating cells derived from cord blood (CB) hematopoietic stem/progenitor cells (HSPC) that provide a myeloid bridge until hematopoietic reconstitution occurs. [3] [4] [5] [6] [7] [8] [9] However, these have relied on real-time expansion of partially HLA-matched units with costs of the unit and manufacturing prohibitive for widespread use. Generation of greater HSPC per starting cell than currently achieved will be required to develop a cryopreserved product able to overcome HLA-matching barriers thereby making it readily and widely available.
immobilized Delta1 Ext-IgG or IgG (2.5 or 5 μg/ml) in StemSpan SFEM and cytokines (IL6, TPO, Flt-3 ligand, SCF (50 ng/ml)) and SR-1 (750nM). 3, 5 Quantitative PCR was performed on ABI PRISM 7700 (Applied Biosystems, NY, USA) with Taqman PCR Master Mix (Applied Biosystems, NY, USA) and primers for HES1 (Hs00172878_m1) and GUSB (Hs00939627_m1). Lentiviral wt-HES1 was a gift from Dr. Liyun Sang, 10 and non-specific lentiviral control from Barbara Varnum-Finney. Sublethally irradiated (275 rad) NOD-SCID IL-2Rγ-null mice (NSG) approved for use by the Fred Hutchinson Cancer Research Center Institutional Animal Care and Use Committee were used for transplant. On average, TNC infused/mouse was 4.25 × 10 6 for Delta1 ext-IgG , 1.88 × 10 7 for SR1, and 4.76 ×10 6 for the combination.
Addition of Delta1 Ext-IgG (5μg/ml) to culture with SR1 significantly decreased generation of TNC as compared to SR1 alone (p<0.05, Figure 1A ) with a trend towards decreased CD34 + cells (p=0.17, Figure 1A ). However, greater numbers of the least mature CD34 + CD38 − CD90 lo population 11 were generated when Delta1 Ext-IgG was present in cultures with SR1 compared to Delta1 Ext-IgG alone (p=0.05) with a trend toward greater numbers compared to SR1 alone (p=0.14, Figure 1A ). Analysis of CD34 + CD38 − CD90 lo , common myeloid progenitors (CMP) and granulocyte-monocyte and megakaryocyteerythrocyte (GMP/MEP) cells 12 ( Figure 1B ) revealed the proportion of CD34 + CD38 − CD90 lo cells in cultures with Delta1 Ext-IgG and SR1 was equivalent to the proportion in cultures with Delta1 Ext-IgG alone (p=0.33); however, both were significantly greater than in cultures with SR1 alone (p=0.04, p=0.02 respectively). In contrast, there was a relatively greater percent of more mature CMP and GMP/MEP cells in culture with SR1 alone as compared to Delta1 Ext-IgG with or without SR1 (p=0.07, p=0.03, respectively), suggesting that Delta1 Ext-IgG is further delaying myeloid differentiation resulting in enhanced generation of the least mature progenitors.
We next determined whether induction of HES1 in cells cultured in the presence of Delta1 Ext-IgG accounted, at least in part, for the ability of Delta1 Ext-IgG to enhance SR1 induced effects on expansion of HSPC. HES1 expression was found to be 3.5-fold higher in cultures with Delta1 Ext-IgG alone compared to IgG control and over 4.5-fold greater than SR1 alone ( Figure 1C ). When Delta1 Ext-IgG was added to cultures with SR1, HES1 induction was nearly 3.5-fold greater than with SR1 alone, suggesting that Delta1 Ext-IgG induces HES1 expression in cells cultured with SR1 and this increase may be responsible at least in part for the delay in differentiation and enhanced early precursor generation seen in these cultures. Interestingly, cells cultured with Delta1 Ext-IgG alone had significantly greater HES1 expression as compared to those cultured in the combination (p=0.0035), possibly due to down-regulation of HES1 expression through AhR antagonism as AhR has been shown to up-regulate HES1 expression. 13 Based on ex vivo studies of murine progenitors demonstrating that over-expression of Hes1 inhibits myeloid differentiation and enhances generation of multi-potent progenitor cells 14 , we determined whether HES1 overexpression in CB HSPC combined with SR1 might phenocopy effects of combining Delta1 Ext-IgG with SR1. We found 5-fold higher HES1 expression in HES1-transduced cells cultured on IgG as compared to control-transduced cells and 2-fold higher expression for HES1 overexpressing cells as compared with control-infected cells in the presence of SR1 (data not shown). Importantly, culture of HES1-transduced cells in the presence of SR1 generated 25-fold more CD34 + CD38 − CD90 lo cells than culture with cells transduced with lenti-control and SR1 ( Figure 1D ). To further illuminate the mechanism whereby HES1 expression affects culture with SR1, we attempted to abrogate HES1 expression through shRNA in CB HSPC cultured in the presence of Delta1 Ext-IgG , SR1 or the combination; however, despite GFP expression consistent with successful transduction of shRNA constructs, HES1 expression was unchanged as compared to control cultures.
We next determined the functional significance of CB HSPC generated in the presence of Delta1 Ext-IgG and/or SR1 by assessing their in vivo repopulating capability in immune deficient mice. We found significantly enhanced rapid myeloid reconstitution 2 weeks after transplantation from cells cultured with the combination in comparison with either factor alone ( Figure 2A ). Limiting dilution transplants revealed a significant nearly 3-fold increase in frequency of RRC able to reconstitute CD33 + myeloid cells in mice that received cells cultured in the presence of Delta1 Ext-IgG and SR1 as compared to either alone based on robust, greater than 5% marrow repopulation that is nearly completely myeloid at this early time post-engraftment (Figure 2A ). At a more limiting level of marrow repopulation (1%), we also found a significant 3-fold difference between cells cultured with SR1 alone and the combination. However, the 1½-fold difference found between cells cultured with Delta1 Ext-IgG alone or in the presence of Delta1 Ext-IgG and SR1 was not statistically significant, suggesting the difference in RRC frequency between SR1 and Delta1 Ext-IgG at a more robust (5%) versus less robust (1%) level of marrow repopulation may reflect generation of less mature precursors with greater proliferative potential. Consistent with this hypothesis, the percent of CD34 + progenitor cells present in the marrow was also significantly greater due to transplantation of cells cultured with both Delta1 Ext-IgG and SR1 compared with SR1 or Delta1 Ext-IgG alone ( Figure 2B ). Further analysis revealed that a higher proportion of the CD34 + cells in the marrow reconstituted with cells cultured with SR1 and Delta1 Ext-IgG were CD33 − compared with those derived from cultures containing SR1 or Delta1 Ext-IgG alone ( Figure 2C ) further suggesting the more primitive nature of the precursors generated by SR1 and Delta1 Ext-IgG .
Of note, rapid repopulation by B-lymphoid cells (percent CD45 + CD33 − CD19 + ) was significantly enhanced by cells cultured in the presence of SR1 alone in comparison with cells cultured with Delta1 Ext-IgG +/− SR1 (data not shown). This may be a result of Notch1-mediated inhibition of the differentiation of multi-potent precursors combined with enhanced generation of immature B-cells due to AhR inhibition as suggested by findings in AhR receptor-null mice. 15 Evaluation of longer term repopulation at 12-14 weeks revealed multi-lineage engraftment in all groups ( Figure 2D ). While overall human engraftment was higher due to cells cultured with Delta1 Ext-IgG and SR1 compared with SR1 or Delta1 Ext-IgG alone ( Figure 2D ), this was primarily due to enhanced B-lymphoid engraftment ( Figure 2D ). It is not clear whether these lymphoid cells were newly derived or represented longer lived cells developed during earlier time points. While low-level CD3 + engraftment was present in all groups at this later time point, it constituted less than 0.6% of total marrow engraftment and was not significantly different between the groups (data not shown). However, it is not known whether differences in engraftment would have been discerned in the presence of human thymic explants in NSG mice. Following secondary transplantation, no differences were found between the groups (average CD45 + 0.22% in Delta1 Ext-IgG , 0.11% in SR1, and 0.18% in the combination, data not shown) demonstrating all three culture conditions generate similar long-term engrafting cells.
Our data indicate that the addition of Delta1 Ext-IgG to SR1 enhances the generation of more robust, rapid repopulating cells. Given the fixed collection volume and cellular yield obtained from an individual cord blood unit, the ability to generate greater numbers of HSPC from a given cord blood unit without increasing the utilization of culture media, cytokines or other costly materials further allows development of cost-effective HSPC expansion methodologies. Moreover, generation of greater numbers of HSPC than currently achieved has the potential to make use of the large inventory of cord blood units currently too small for clinical application. This will be critical when developing cellular therapy for treating neutropenia outside of the CBT setting. 
